{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:20:54Z","timestamp":1777911654243,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2024.01.008","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T08:21:31Z","timestamp":1706516491000},"page":"549-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Elexacaftor\/tezacaftor\/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-6360","authenticated-orcid":false,"given":"Renske","family":"van der Meer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik B","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot N","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena M","family":"Paalvast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-9316","authenticated-orcid":false,"given":"Matthijs","family":"van Luin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C J M","family":"van Rossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry G M","family":"Heijerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.jcf.2024.01.008_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2024.01.008_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.01.008_bib0003","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.01.008_bib0004","unstructured":"Kaftrio. Summary of product characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/kaftrio-epar-product-information."},{"key":"10.1016\/j.jcf.2024.01.008_bib0005","unstructured":"Kalydeco. Summary of product characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/kalydeco-epar-product-information."},{"issue":"1","key":"10.1016\/j.jcf.2024.01.008_bib0006","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.jcf.2021.05.008","article-title":"Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis","volume":"21","author":"Smith","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2024.01.008_bib0007","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.008_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.008_bib0009","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","article-title":"Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf","volume":"71","author":"Woillard","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.008_bib0010","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/pharmaceutics15051438","article-title":"Application of physiologically based pharmacokinetic modeling to predict drug-drug interactions between elexacaftor\/tezacaftor\/ivacaftor and tacrolimus in lung transplant recipients","volume":"15","author":"Hong","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.008_bib0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis","volume":"21","author":"McKinzie","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.008_bib0012","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ppul.25779","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: a case series","volume":"57","author":"Ragan","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2024.01.008_bib0013","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.008_bib0014","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jcf.2022.11.008","article-title":"The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis","volume":"22","author":"van der Meer","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.008_bib0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.01.008_bib0016","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.008_bib0017","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jcf.2014.07.013","article-title":"Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508\/S1215N","volume":"14","author":"Vreede","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.01.008_bib0018","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2021","journal-title":"J Clin Transl Endocrinol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:31:39Z","timestamp":1777649499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199324000079"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}